Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etanercept biosimilar - Sunshine Guojian Pharmaceutical

Next Previous
X
Search
Drug Profile

Etanercept biosimilar - Sunshine Guojian Pharmaceutical

Alternative Names: 301-S; Etacept; Etanar; Reumatocept®; Yisaipu

Latest Information Update: 28 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai CP Guojian Pharmaceutical
  • Developer Cipla; Sunshine Guojian Pharmaceutical
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 24 Feb 2021 EMS withdraws the phase III trial for Rheumatoid arthritis in Brazil as per sponsor decision (NCT01394913)
  • 20 Mar 2019 3SBio plans to file for manufacturing approval for a prefilled syringe dosage form of etanercept biosimilar in China, in the first half of 2019
  • 01 Mar 2016 Launched for Plaque psoriasis in India (SC) before March 2016

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top